Novocure LTD 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

26 Feb 2026

NVCR

10-K: NovoCure 2025 Annual Report: Revenue Growth Amid R&D Investment

NovoCure Limited reports 8% revenue growth to $655.4 million in 2025, driven by Optune Gio adoption and new product launches, despite continued operating losses and increased R&D spending.

NASDAQ

27 Feb 2025

NVCR

Novocure LTD

10-K: NovoCure Reports FY2024 Results, Driven by Growth in Key Markets and Clinical Advancements

NovoCure's 10-K filing highlights a year of revenue growth, clinical trial progress, and strategic pipeline expansion, balanced against ongoing operating losses and market competition.

NASDAQ

22 Feb 2024

NVCR

Novocure LTD

10-K: NovoCure Limited 2023 Annual Report: Solid Progress in Oncology, Eyes NSCLC Approval

NovoCure's 2023 annual report highlights progress in commercializing its Tumor Treating Fields (TTFields) therapy and advancing clinical trials, with a focus on potential approval for non-small cell lung cancer (NSCLC).